Ravenstijn, Paulien

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

Ravenstijn, P., Remmerie, B., Savitz, A., Samtani, M. N., Nuamah, I., Chang, C., De Meulder, M., Hough, D., & Gopal, S. (2016) · The Journal of Clinical Pharmacology

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 86

Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations

Russu, A., Kern Sliwa, J., Ravenstijn, P., Singh, A., Mathews, M., Kim, E., & Gopal, S. (2018) · International Journal of Clinical Practice

Schizophrenia research and treatmentPharmaceutical studies and practices

Cited by 19